|
| Status |
Public on Dec 01, 2017 |
| Title |
Liver DGE analysis of hemophilia mice (hFIX9-R29X) treated with ASOs inhibiting NMD |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
To evaluate the impact of ASO-mediated depletion of NMD factor Upf1 and Upf3b on the normal transcriptome, we performed digital gene expression analysison hFIX-R29X mouse liver treated with Upf3b-GalNAc-ASO.
|
| |
|
| Overall design |
hFIX-R29X mice 8-14 weeks of age (n=5-6, 2-3 female and 2-3 male mice per group) were treated every 5 days with 6 doses of DPBS, Control-GalNAc-ASO (15 or 20mg/kg), Upf1-GalNAc-ASO (20 mg/kg) and Upf3b-GalNAc-ASO (10 or 20 mg/kg). Animals were sacrificed 48 h after the last dose.
|
| |
|
| Contributor(s) |
Huang L, Damle S |
| Citation(s) |
29334995 |
| |
| Submission date |
Jun 02, 2017 |
| Last update date |
Jul 25, 2021 |
| Contact name |
Sagar S Damle |
| E-mail(s) |
sdamle@ionisph.com
|
| Organization name |
Ionis Pharmaceuticals
|
| Street address |
2855 Gazelle Ct
|
| City |
Carlsbad |
| State/province |
CA |
| ZIP/Postal code |
92010 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL19057 |
Illumina NextSeq 500 (Mus musculus) |
|
| Samples (33)
|
|
| Relations |
| BioProject |
PRJNA388971 |
| SRA |
SRP108495 |
Less...
More...